ofloxacin and Community Acquired Infection studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Research Excerpts

Excerpt	Relevance	Reference
"Levofloxacin has established efficacy and safety in the treatment of community-acquired pneumonia (CAP) in adults, and its use as an alternative therapy for children with CAP has been proposed."	9.12	Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. ( Arguedas, A; Blumer, JL; Bradley, JS; Melkote, R; Noel, GJ; Sáez-Llorens, X, 2007)
"In this study, we analyzed 302 patients with pneumonia admitted to the Intensive Care Unit (ICU) who were treated with levofloxacin (LFX) either as monotherapy or combined therapy."	9.11	Levofloxacin in the treatment of pneumonia in intensive care unit patients. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sanchez, M, 2004)
"This subgroup analysis sought to determine the efficacy and tolerability of a 5-day regimen of levofloxacin 750 mg/d compared with a 10-day regimen of levofloxacin 500 mg/d in the treatment of community-acquired pneumonia (CAP) in elderly patients (aged > or =65 years)."	9.11	A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. ( Shorr, AF; Tennenberg, AM; Wes Ely, E; Xiang, JX; Zadeikis, N, 2005)
"0-g oral dose of a novel microsphere formulation of azithromycin was at least as effective as 7 days of levofloxacin, 500 mg/day, in the treatment of adult patients with mild to moderate community-acquired pneumonia (Fine classes I, II, and III)."	9.11	Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. ( Breen, JD; Camere, MA; D'Ignazio, J; Jorgensen, D; Lewis, DE, 2005)
"Levofloxacin, an antibiotic from the quinolone family, which is used with success in the ambulatory treatment of patients with community-acquired pneumonia, has been recently introduced to the pharmaceutical market."	9.09	[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]. ( Bagilet, D; Diab, M; Javkin, E; Kalbermatter, V, 2000)
"A malnourished 58-year-old man with diabetes developed hypoglycemia after receiving levofloxacin in conjunction with glipizide."	7.75	Hypoglycemia associated with the use of levofloxacin. ( Garber, SM; Miller, SM; Pound, MW, 2009)
"The aim of this study was to evaluate the in vitro activity of levofloxacin (LVX) in comparison to nalidixic acid (NAL), ofloxacin (OFX), norfloxacin (NOR), amoxicillin (AMX), cefixime (CFM), cotrimoxazole (SXT) and nitrofurantoin (FT), against 402 strains recently isolated from urine specimens in outpatient women suffering from lower urinary tract infections for which short-term treatment was not indicated."	7.73	[Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. ( Dib, C; Durand, C; Moniot-Ville, N; Weber, P, 2005)
"The influence of patient relevant parameters such as age, comorbidity, or duration of disease on the treatment success of levofloxacin for community-acquired respiratory tract infections (CARTI) has not been thoroughly elucidated."	7.72	The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. ( Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R, 2003)
"We describe the first case of failure of oral levofloxacin treatment of community-acquired pneumonia caused by Haemophilus influenzae."	7.72	Levofloxacin treatment failure in Haemophilus influenzae pneumonia. ( Alonso-Tarrés, C; Bastida, T; Campos, J; Cortés-Lletget, MC; de la Campa, AG; Pérez-Vázquez, M; Román, F; Tubau, F, 2003)
"THE EFFICACY OF LEVOFLOXACIN: In treating community-acquired pneumonia (CAP) has been assessed during 5 large clinical trials (including 4 controlled randomized trials)."	7.71	[Update on the role of levofloxacin in the management of acute community-acquired pneumonia]. ( Bru, JP, 2002)
"Forty patients were treated with ofloxacin for community acquired lower respiratory tract infections."	7.70	Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation. ( Aziah, AM; Liam, CK; Lim, KH; Wong, CM, 2000)
" More patients treated with levofloxacin than with solithromycin experienced treatment-emergent adverse events (TEAEs) during the study (45."	6.78	Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. ( Clark, K; Craft, JC; Das, A; Fernandes, P; Jamieson, BD; Oldach, D; Schranz, J; Scott, D, 2013)
"Levofloxacin was as well tolerated as azithromycin, with an incidence of drug-related adverse events (AEs) for all body systems of 5."	6.70	A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. ( Bahal, N; Frank, E; Freitag, S; Kahn, JB; Kinasewitz, G; Liu, J; Moran, GJ; Olson, WH; Oross, MP; Reichl, V; Tennenberg, A; Wiesinger, BA, 2002)
" Its improved bioavailability and safety profile makes the possibility of shorter hospital stays a reality."	6.48	Levofloxacin for the treatment of respiratory tract infections. ( Liapikou, A; Torres, A, 2012)
" The high bioavailability of levofloxacin allows for rapid step-down from intravenous administration to oral therapy, minimizing unnecessary hospitalization, which may decrease costs and improve patient quality of life."	6.43	Levofloxacin for the treatment of community-acquired pneumonia. ( File, TM; Lynch, JP; Zhanel, GG, 2006)
"Two of the most serious respiratory tract infections are community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB)."	6.43	Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. ( Cantón, R; Graninger, W; Lode, H; Milkovich, G, 2006)
"On suspecting Achilles tendinitis, levofloxacin treatment was discontinued, and the tendinitis subsequently improved."	5.36	Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions. ( Baek, YS; Cheong, MH; Durey, A; Lee, JS; Lee, K; Park, JS; Ryu, JS, 2010)
" Average length of stay (LOS), hospital costs, death rate, age, and ratio of oral to intravenous dosage administration were analyzed."	5.31	Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. ( Clark, LC; Davis, CW, 2000)
"Levofloxacin has established efficacy and safety in the treatment of community-acquired pneumonia (CAP) in adults, and its use as an alternative therapy for children with CAP has been proposed."	5.12	Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. ( Arguedas, A; Blumer, JL; Bradley, JS; Melkote, R; Noel, GJ; Sáez-Llorens, X, 2007)
"In this study, we analyzed 302 patients with pneumonia admitted to the Intensive Care Unit (ICU) who were treated with levofloxacin (LFX) either as monotherapy or combined therapy."	5.11	Levofloxacin in the treatment of pneumonia in intensive care unit patients. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sanchez, M, 2004)
"0-g oral dose of a novel microsphere formulation of azithromycin was at least as effective as 7 days of levofloxacin, 500 mg/day, in the treatment of adult patients with mild to moderate community-acquired pneumonia (Fine classes I, II, and III)."	5.11	Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. ( Breen, JD; Camere, MA; D'Ignazio, J; Jorgensen, D; Lewis, DE, 2005)
"This subgroup analysis sought to determine the efficacy and tolerability of a 5-day regimen of levofloxacin 750 mg/d compared with a 10-day regimen of levofloxacin 500 mg/d in the treatment of community-acquired pneumonia (CAP) in elderly patients (aged > or =65 years)."	5.11	A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. ( Shorr, AF; Tennenberg, AM; Wes Ely, E; Xiang, JX; Zadeikis, N, 2005)
"Levofloxacin, an antibiotic from the quinolone family, which is used with success in the ambulatory treatment of patients with community-acquired pneumonia, has been recently introduced to the pharmaceutical market."	5.09	[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]. ( Bagilet, D; Diab, M; Javkin, E; Kalbermatter, V, 2000)
"The efficacy and safety of a 3-day regimen of sparfloxacin were compared with those of a 3-day regimen of ofloxacin for the treatment of community-acquired acute uncomplicated urinary tract infections."	5.08	Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. ( Dorr, MB; Ellison, W; Henry, D; Magner, DJ; Mansfield, DL; Sullivan, J; Talbot, GH, 1998)
"Strains isolated in health-related bacteriuria are more frequently ofloxacin resistant principally because of the greater proportion of Gram positive bacteria and because of a non-significant higher ofloxacin resistance rate among Enterobacteriaceae."	3.78	[Differences between species involved and fluoroquinolone resistance patterns of strains isolated from bacteriuria according to nosocomial, health-related or community-acquired onset]. ( Batalla, AS; De Champs, C; Duval, V; Guillard, T; N'Guyen, Y; Strady, C; Tassain, J, 2012)
"CAP episodes were identified in the PharMetrics database between 2Q04 and 2Q07 based on: pneumonia diagnosis, chest X-ray and treatment with levofloxacin or moxifloxacin."	3.76	Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. ( Fisher, AC; Grant, R; Gu, A; Mody, SH; Ng, D; Raut, M; Schein, J; Sengupta, A; Sheng Duh, M; Signorovitch, JE, 2010)
"Levofloxacin (levogyre form of ofloxacin) has been approved for the treatment of acute and chronic sinusitis, pneumonia, and exacerbation of bronchopulmonary diseases, urinary, digestive and biliary infections in adults."	3.76	[Levofloxacin in children]. ( Cohen, R; Grimprel, E, 2010)
"A malnourished 58-year-old man with diabetes developed hypoglycemia after receiving levofloxacin in conjunction with glipizide."	3.75	Hypoglycemia associated with the use of levofloxacin. ( Garber, SM; Miller, SM; Pound, MW, 2009)
"The aim of this study was to evaluate the in vitro activity of levofloxacin (LVX) in comparison to nalidixic acid (NAL), ofloxacin (OFX), norfloxacin (NOR), amoxicillin (AMX), cefixime (CFM), cotrimoxazole (SXT) and nitrofurantoin (FT), against 402 strains recently isolated from urine specimens in outpatient women suffering from lower urinary tract infections for which short-term treatment was not indicated."	3.73	[Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. ( Dib, C; Durand, C; Moniot-Ville, N; Weber, P, 2005)
"The influence of patient relevant parameters such as age, comorbidity, or duration of disease on the treatment success of levofloxacin for community-acquired respiratory tract infections (CARTI) has not been thoroughly elucidated."	3.72	The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. ( Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R, 2003)
"We describe the first case of failure of oral levofloxacin treatment of community-acquired pneumonia caused by Haemophilus influenzae."	3.72	Levofloxacin treatment failure in Haemophilus influenzae pneumonia. ( Alonso-Tarrés, C; Bastida, T; Campos, J; Cortés-Lletget, MC; de la Campa, AG; Pérez-Vázquez, M; Román, F; Tubau, F, 2003)
"THE EFFICACY OF LEVOFLOXACIN: In treating community-acquired pneumonia (CAP) has been assessed during 5 large clinical trials (including 4 controlled randomized trials)."	3.71	[Update on the role of levofloxacin in the management of acute community-acquired pneumonia]. ( Bru, JP, 2002)
"The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections."	3.71	Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. ( Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V, 2001)
"This study was conducted to evaluate the activity of levofloxacin in comparison with a range of antibacterial agents against recent isolates obtained consecutively from patients with community-acquired pneumonia (CAP) or acute exacerbation of chronic bronchitis (AECB) during the period 1995 to 1996."	3.70	Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. ( Ariza, H; Ascoli, M; Casellas, JM; Dolmann, A; Gilardoni, M; Goldberg, M; Ivanovic, S; Montero, JM; Orduna, M; Tome, G, 1999)
"Forty patients were treated with ofloxacin for community acquired lower respiratory tract infections."	3.70	Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation. ( Aziah, AM; Liam, CK; Lim, KH; Wong, CM, 2000)
" More patients treated with levofloxacin than with solithromycin experienced treatment-emergent adverse events (TEAEs) during the study (45."	2.78	Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. ( Clark, K; Craft, JC; Das, A; Fernandes, P; Jamieson, BD; Oldach, D; Schranz, J; Scott, D, 2013)
" The results indicate that LVFX dosage adjustment should be individualized on the basis of the CL(cr), especially in those with CL(cr) less than 50 ml/min."	2.74	Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ( Cao, GY; Huang, JA; Liu, YB; Shi, YG; Si, B; Sun, SH; Wu, XJ; Xia, QM; Xiao, ZK; Xu, JF; Zhang, J; Zhang, YY, 2009)
" Nausea, vomiting, and diarrhoea were the most frequently reported adverse events."	2.74	Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. ( Calistru, PI; Castaing, N; Chernyak, V; Cooper, CA; Dartois, N; Gandjini, H; Milutinovic, S; Strausz, J; Tanaseanu, C; Zolubas, M, 2009)
"Levofloxacin's efficacy was inferior to azithromycin's efficacy, except in patients with no pathogen identified during the first 24 h of treatment or in patients with levofloxacin-susceptible Campylobacter isolates, in whom it appeared to be equal to azithromycin."	2.73	Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. ( Armstrong, A; Baqar, S; Bodhidatta, L; Faix, DJ; Fox, A; Hshieh, P; Lawler, JV; Lebron, C; Lewis, M; Maley, EA; Mason, C; Nayak, G; Pang, LW; Pitarangsi, C; Sanders, JW; Scott, DA; Tribble, DR, 2007)
" There were no statistically significant differences between the treatment groups with regard to drug-related adverse events."	2.72	Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. ( Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI, 2006)
" This subgroup analysis attempted to compare the safety and efficacy of a short-course levofloxacin regimen with traditional levofloxacin dosing for PSI Class III/IV patients."	2.72	Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. ( Kahn, JB; Khashab, MM; Shorr, AF; Tennenberg, AM; Xiang, JX, 2006)
"Our results suggest that in critically ill patients who are receiving mechanical ventilation and have severe community-acquired pneumonia and creatinine clearance of >40 mL/min, the administration of 500 mg of intravenous levofloxacin once and twice daily allows for the exceeding of pharmacodynamic thresholds predictive of outcome (i."	2.71	Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ( Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Djabarouti, S; Rimmelé, T; Saux, MC, 2005)
"One moxifloxacin-treated patient had sustained monomorphic VT (> 30 s), and one levofloxacin-treated patient had torsade de pointes."	2.71	A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. ( Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS, 2005)
"Levofloxacin was as well tolerated as azithromycin, with an incidence of drug-related adverse events (AEs) for all body systems of 5."	2.70	A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. ( Bahal, N; Frank, E; Freitag, S; Kahn, JB; Kinasewitz, G; Liu, J; Moran, GJ; Olson, WH; Oross, MP; Reichl, V; Tennenberg, A; Wiesinger, BA, 2002)
"Levofloxacin is a new fluoroquinolone active against S."	2.69	[Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]. ( Léophonte, P; Veyssier, P, 1999)
" Drug-related adverse events were reported in 5."	2.68	A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. ( Dunbar, L; File, TM; Kohler, R; Kojak, C; Player, R; Rubin, A; Segreti, J; Williams, RR, 1997)
" Its improved bioavailability and safety profile makes the possibility of shorter hospital stays a reality."	2.48	Levofloxacin for the treatment of respiratory tract infections. ( Liapikou, A; Torres, A, 2012)
"Levofloxacin is a fluoroquinolone that has a broad spectrum of activity against several causative bacterial pathogens of community-acquired pneumonia (CAP)."	2.46	Levofloxacin in the treatment of community-acquired pneumonia. ( Elkhatib, WF; Noreddin, AM, 2010)
"Clinical manifestations of Legionnaires' disease are not specific and current diagnostic scores are of limited use."	2.46	An update on Legionella. ( Carratalà, J; Garcia-Vidal, C, 2010)
"Levofloxacin (Levaquin) is a fluoroquinolone antibacterial that is the L-isomer of ofloxacin."	2.44	Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection. ( Anderson, VR; Perry, CM, 2008)
"For levofloxacin-treated CAP patients with P."	2.43	Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. ( Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC, 2006)
"Two of the most serious respiratory tract infections are community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB)."	2.43	Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. ( Cantón, R; Graninger, W; Lode, H; Milkovich, G, 2006)
" The high bioavailability of levofloxacin allows for rapid step-down from intravenous administration to oral therapy, minimizing unnecessary hospitalization, which may decrease costs and improve patient quality of life."	2.43	Levofloxacin for the treatment of community-acquired pneumonia. ( File, TM; Lynch, JP; Zhanel, GG, 2006)
" Adherence to the prescribed regimen is affected by a number of variables including dosing interval, treatment duration, adverse effects, and palatability in pediatric patients."	2.43	Value of short-course antimicrobial therapy in community-acquired pneumonia. ( Blasi, F; Tarsia, P, 2005)
"Levofloxacine is a fluoroquinolone presenting good anti-pneumococcal activity, including against strains with reduced sensitivity to penicillin."	2.42	[Levofloxacine for the treatment of pneumococcal pneumonia: results of a meta-analysis]. ( Bru, JP; Leophonte, P; Veyssier, P, 2003)
" In the face of rising MICs (as is occurring worldwide with Streptococcus pneumoniae), close attention to appropriate dosing and concentration above the MIC may delay and potentially even prevent antibiotic resistance."	2.41	What have we learned from pharmacokinetic and pharmacodynamic theories? ( Gilliland, KK; Paladino, JA; Schentag, JJ, 2001)
"Levofloxacin resistance was associated with increased mortality, along with septic shock, prior use of corticosteroids, and development of ARDS, in adult patients with IPD."	1.39	Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort. ( Carlos, CC; Chung, DR; Hsueh, PR; Kang, CI; Kim, SH; Peck, KR; Perera, J; So, TM; Song, JH; Thamlikitkul, V; Van, PH; Wang, H; Yasin, RM, 2013)
"We describe multiple brain abscesses due to P."	1.37	Brain abscesses during Proteus vulgaris bacteremia. ( Bloch, J; Ferriby, D; Legout, L; Lemaire, X; Senneville, E; Yazdanpanah, Y, 2011)
"On suspecting Achilles tendinitis, levofloxacin treatment was discontinued, and the tendinitis subsequently improved."	1.36	Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions. ( Baek, YS; Cheong, MH; Durey, A; Lee, JS; Lee, K; Park, JS; Ryu, JS, 2010)
"Amoxicillin was prescribed in 108 cases, fluoroquinolone in 24 cases, macrolide in 18 cases."	1.36	[Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia]. ( Bernardin, G; Cua, E; de Salvador, F; Dellamonica, J; Hyvernat, H; Landraud, L; Risso, K; Roger, PM; Vassallo, M, 2010)
"An analysis of patients with Legionnaires' disease from the Community-Acquired Pneumonia Organization database was performed."	1.36	Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. ( Arnold, F; Griffin, AT; Peyrani, P; Wiemken, T, 2010)
" By the antibacterial activity and bioavailability sodium furasidin is advantages among the nitrofurans."	1.33	[Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I]. ( Ivanov, DV; Sidorenko, SV, 2005)
" Dosing regimens for gatifloxacin were 400 mg once daily (qd) administered to younger patients (<65 years) and gatifloxacin 200 mg qd to elderly patients (> or =65 years)."	1.33	Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ( Hoban, DJ; Noreddin, AM; Zhanel, GG, 2005)
"Levofloxacin treatment was supplemented with piperacillin/tazobactam."	1.33	Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. ( Bettaccini, AA; Brigante, G; Endimiani, A; Grossi, P; Luzzaro, F; Toniolo, AQ, 2005)
" A pharmacokinetic computerized device was used to simulate serum and epithelial lining fluid (ELF) concentrations."	1.33	A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. ( Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D, 2006)
" Adverse events were mild."	1.33	[Efficacy and safety of levofloxacin treatment of community--acquired pneumonia in hospitalized patients]. ( Chazan, R; Grabczak, M; Karwat, KJ, 2006)
"Levofloxacin was efficacious at both 500 mg for 7 to 14 days and 750 mg for 5 days."	1.32	Levofloxacin efficacy in the treatment of community-acquired legionellosis. ( Greenberg, RN; Khashab, MM; Olson, WH; Stout, JE; Tennenberg, AM; Yu, VL; Zadeikis, N, 2004)
" This work aimed at assessing the pharmacodynamic target attainment against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg administered once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia."	1.32	Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ( Chan, CK; Hoban, DJ; Marras, TK; Noreddin, AM; Sanders, K; Zhanel, GG, 2004)
"We describe two patients with systemic lupus erythematosus (SLE) who presented with fever, systemic upset and pulmonary infiltrates between April and June, 2003."	1.32	Lupus pneumonitis or severe acute respiratory syndrome? ( Mok, CC; Ying, KY, 2004)
"Levofloxacin was predominantly prescribed for treating community-acquired infections (67."	1.32	[Observational study investigating the use of levofloxacin in ICU patients]. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sánchez, M, 2004)
"Levofloxacin is an additional option as monotherapy for the treatment of CAP."	1.31	Oral levofloxacin in the treatment of community-acquired pneumonia. ( Idrahim, KY; Lima Nicodemo, E; Nicodemo, AC, 2000)
" Average length of stay (LOS), hospital costs, death rate, age, and ratio of oral to intravenous dosage administration were analyzed."	1.31	Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. ( Clark, LC; Davis, CW, 2000)
"In vitro and in vivo models of infection suggest that the area under the concentration-time curve (AUC): minimum inhibitory concentration (MIC) ratio is the pharmacodynamic parameter that is most predictive of bactericidal activity for the fluoroquinolones."	1.31	Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. ( Ambrose, PG; Nicolau, DP, 2001)
"Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) are mild-to-life-threatening adverse reactions that have been described after exposure to fluoroquinolones."	1.31	Levofloxacin-induced toxic epidermal necrolysis in an elderly patient. ( Ackerman, BH; Cawley, MJ; Digwood-Lettieri, S; Guilday, RJ; Haith, LR; Patton, ML; Reilly, KJ, 2002)
" The mean peak concentration and the mean AUC values normalized to a dosage of 500 mg every 24 h were 8."	1.30	Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. ( Berman, AL; Chow, AT; Corrado, M; Dornseif, B; Drusano, GL; Fowler, CL; Natarajan, J; Preston, SL; Reichl, V; Wong, FA, 1998)

Research

Studies (168)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Time to Clinical Stability

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	14 (8.33)	18.2507
2000's	124 (73.81)	29.6817
2010's	29 (17.26)	24.3611
2020's	1 (0.60)	2.80

Authors	Studies
Mendonça, N	1
Leitão, J	1
Manageiro, V	1
Ferreira, E	1
Caniça, M	1
Akinpelu, S	1
Ajayi, A	1
Smith, SI	1
Adeleye, AI	1
Oldach, D	1
Clark, K	1
Schranz, J	1
Das, A	1
Craft, JC	1
Scott, D	1
Jamieson, BD	1
Fernandes, P	1
Bedoin, M	1
Cazorla, C	1
Lucht, F	1
Berthelot, P	1
Boyer, M	1
Carricajo, A	1
Guérin, T	1
Viallon, A	1
Wang, JY	1
Lee, CH	1
Yu, MC	1
Lee, MC	1
Lee, LN	1
Wang, JT	1
Llop, CJ	1
Tuttle, E	1
Tillotson, GS	1
LaPlante, K	1
File, TM	8
Tanaseanu, C	2
Bergallo, C	2
Teglia, O	2
Jasovich, A	2
Oliva, ME	2
Dukart, G	2
Dartois, N	3
Cooper, CA	2
Gandjini, H	3
Mallick, R	2
Trad, S	1
Saadoun, D	1
Barete, S	1
Frances, C	1
Piette, JC	1
Wechsler, B	1
Lentnek, A	1
de Wouters, L	1
Zlocowski, JC	1
Cooper, A	2
Castaing, N	2
Stefani, S	1
Bongiorno, D	1
Cafiso, V	1
Campanile, F	1
Crapis, M	1
Cristini, F	1
Sartor, A	1
Scarparo, C	1
Spina, D	1
Viale, P	1
Frei, CR	1
Jaso, TC	1
Mortensen, EM	1
Restrepo, MI	2
Raut, MK	2
Oramasionwu, CU	1
Ruiz, AD	1
Makos, BR	1
Ruiz, JL	1
Attridge, RT	1
Mody, SH	2
Fisher, A	1
Schein, JR	3
Vila-Corcoles, A	1
Bejarano-Romero, F	1
Salsench, E	1
Ochoa-Gondar, O	1
de Diego, C	1
Gomez-Bertomeu, F	1
Raga-Luria, X	1
Cliville-Guasch, X	1
Arija, V	1
Tattevin, P	1
Basuino, L	1
Chambers, HF	1
Garber, SM	1
Pound, MW	1
Miller, SM	1
Rapp, RP	1
Milutinovic, S	1
Calistru, PI	1
Strausz, J	1
Zolubas, M	1
Chernyak, V	1
Regalado, NG	1
Martin, G	1
Antony, SJ	1
Hsieh, YC	1
Chang, LY	1
Huang, YC	1
Lin, HC	1
Huang, LM	1
Hsueh, PR	3
Torralba, MÁ	1
Matía, M	1
Gómez del Valle, C	1
Pérez-Calvo, JI	1
Zhang, J	1
Xu, JF	1
Liu, YB	1
Xiao, ZK	1
Huang, JA	1
Si, B	1
Sun, SH	1
Xia, QM	1
Wu, XJ	1
Cao, GY	1
Shi, YG	1
Zhang, YY	1
Signorovitch, JE	1
Sheng Duh, M	1
Sengupta, A	1
Gu, A	1
Grant, R	3
Raut, M	1
Schein, J	2
Fisher, AC	2
Ng, D	1
Carratalà, J	3
Garcia-Vidal, C	1
Roger, PM	1
Risso, K	1
Hyvernat, H	1
Landraud, L	1
Vassallo, M	1
Dellamonica, J	1
de Salvador, F	1
Cua, E	1
Bernardin, G	1
Griffin, AT	1
Peyrani, P	1
Wiemken, T	2
Arnold, F	1
Durey, A	1
Baek, YS	1
Park, JS	1
Lee, K	1
Ryu, JS	1
Lee, JS	1
Cheong, MH	1
Blasi, F	3
Petrosillo, N	1
Noreddin, AM	3
Elkhatib, WF	1
Mokabberi, R	1
Haftbaradaran, A	1
Ravakhah, K	1
Hess, G	1
Hill, JW	1
Mody, S	1
Chen, CC	1
Grimprel, E	1
Cohen, R	1
Fernández-Ruiz, M	1
Cervera, C	1
Pitart, C	1
Pérez, G	1
del Río, A	1
Miró, JM	1
Marco, F	1
Moreno, A	1
Bloch, J	1
Lemaire, X	1
Legout, L	1
Ferriby, D	1
Yazdanpanah, Y	1
Senneville, E	1
Wispelwey, B	1
Schafer, KR	1
Rókusz, L	1
Samuel, V	1
Bajwa, AA	1
Cury, JD	1
Guchev, IA	1
Melekhina, EV	1
Iudenich, OV	1
Chuang, TY	1
Lin, CJ	1
Lee, SW	1
Chuang, CP	1
Jong, YS	1
Chen, WJ	1
Biedenbach, DJ	1
Farrell, DJ	2
Flamm, RK	1
Liverman, LC	1
McIntyre, G	1
Jones, RN	3
Torres, A	4
Liapikou, A	1
Gharabaghi, MA	1
Abdollahi, SM	1
Safavi, E	1
Abtahi, SH	1
Tassain, J	1
N'Guyen, Y	1
Batalla, AS	1
Duval, V	1
Guillard, T	1
De Champs, C	1
Strady, C	1
Lee, JH	1
Kim, SW	1
Kim, JH	1
Ryu, YJ	1
Chang, JH	1
Ramirez, JA	1
Cooper, AC	1
Gardiner, D	1
Babinchak, T	1
Kang, CI	1
Song, JH	1
Kim, SH	1
Chung, DR	1
Peck, KR	1
Thamlikitkul, V	1
Wang, H	2
So, TM	1
Yasin, RM	1
Carlos, CC	1
Van, PH	1
Perera, J	1
Bru, JP	3
Frank, E	1
Liu, J	1
Kinasewitz, G	1
Moran, GJ	1
Oross, MP	1
Olson, WH	2
Reichl, V	2
Freitag, S	1
Bahal, N	1
Wiesinger, BA	2
Tennenberg, A	1
Kahn, JB	4
Ruiz, A	1
Falguera, M	1
Sacristán, O	1
Vallverdú, M	1
Cabré, X	1
Pérez, J	1
Ferrer, G	1
Geijo Martínez, MP	1
Díaz de Tuesta Chow-Quan, AM	1
Herranz, CR	1
Gómez Criado, C	1
Dimas Nuñez, JF	1
Saiz García, F	1
Gopal Rao, G	1
Mahankali Rao, CS	1
Starke, I	1
Odagiri, S	1
Watanuki, Y	1
Takahashi, H	1
Shimada, J	1
Malcolm, C	1
Marrie, TJ	6
Burgmann, H	1
Mayer, B	1
Lukas, A	1
Kumbein, F	1
Oberbauer, R	1
Gonzales, R	1
Anderson, KB	1
Tan, JS	1
DiPersio, JR	1
Willey, BM	1
Low, DE	1
Dunbar, LM	2
Wunderink, RG	1
Habib, MP	1
Smith, LG	1
Tennenberg, AM	7
Khashab, MM	5
Xiang, JX	5
Zadeikis, N	5
d'Escrivan, T	1
Roussel-Delvallez, M	1
Alfandari, S	1
Guery, B	1
Bastida, T	1
Pérez-Vázquez, M	1
Campos, J	1
Cortés-Lletget, MC	1
Román, F	1
Tubau, F	1
de la Campa, AG	1
Alonso-Tarrés, C	1
Erard, V	2
Lamy, O	2
Bochud, PY	1
Bille, J	1
Cometta, A	2
Calandra, T	2
Leophonte, P	2
Veyssier, P	2
Alvarez-Lerma, F	2
Palomar, M	2
Olaechea, P	2
León, C	2
Sánchez, M	2
Bermejo, B	2
Martinez, FJ	1
Yu, YS	1
Liu, Y	1
Li, HY	1
Hu, BJ	1
Sun, ZY	1
Chen, MJ	1
Yu, VL	1
Greenberg, RN	2
Stout, JE	1
Mok, CC	1
Ying, KY	1
Milkovich, G	3
Wasserfallen, JB	1
Marras, TK	1
Sanders, K	1
Chan, CK	1
Hoban, DJ	2
Zhanel, GG	3
Brown, SD	1
Morrissey, I	1
Zervos, M	1
Mandell, LA	1
Vrooman, PS	1
Andrews, CP	1
McIvor, A	1
Abdulla, RH	1
de Caprariis, PJ	1
Knirsch, CA	1
Amsden, GW	1
Niederman, MS	3
Lode, H	3
Querol-Ribelles, JM	1
Tenías, JM	1
Querol-Borrás, JM	1
Labrador, T	1
Nieto, A	1
González-Granda, D	1
Martínez, I	1
Bhavnani, SM	1
Hammel, JP	1
Ambrose, PG	3
Boselli, E	1
Breilh, D	1
Rimmelé, T	1
Djabarouti, S	1
Saux, MC	1
Chassard, D	1
Allaouchiche, B	1
Fernández-Sabé, N	1
Ortega, L	1
Castellsagué, X	1
Rosón, B	1
Dorca, J	1
Fernández-Agüera, A	1
Verdaguer, R	1
Martínez, J	1
Manresa, F	1
Gudiol, F	1
Mandell, L	1
Weber, P	1
Dib, C	1
Durand, C	1
Moniot-Ville, N	1
Skrepnek, GH	1
Armstrong, EP	1
Malone, DC	1
Ramachandran, S	1
Carlavilla, AB	1
López-Medrano, F	1
Chaves, F	1
Villena, V	1
Echave-Sustaeta, J	1
Aguado, JM	1
Arnold, FW	1
Wojda, B	1
Fritsche, TR	1
Sader, HS	1
Leroy, O	1
Saux, P	1
Bédos, JP	1
Caulin, E	1
D'Ignazio, J	1
Camere, MA	1
Lewis, DE	1
Jorgensen, D	1
Breen, JD	1
Shorr, AF	2
Wes Ely, E	1
Sidorenko, SV	1
Ivanov, DV	1
Milbrandt, EB	1
Angus, DC	1
Samsa, GP	1
Matchar, DB	1
Harnett, J	1
Wilson, J	1
Morganroth, J	1
Dimarco, JP	1
Anzueto, A	2
Choudhri, S	2
Endimiani, A	1
Brigante, G	1
Bettaccini, AA	1
Luzzaro, F	1
Grossi, P	1
Toniolo, AQ	1
Pearle, J	1
Heyder, A	1
Choudhri, SH	1
Pavié G, J	1
Prida C, JM	1
Díaz F, A	1
Saldías P, F	1
Ramdani-Bouguessa, N	1
Bes, M	1
Meugnier, H	1
Forey, F	1
Reverdy, ME	1
Lina, G	1
Vandenesch, F	1
Tazir, M	1
Etienne, J	1
Tarsia, P	1
Martín-Herrero, JE	1
Mykietiuk, A	1
García-Rey, C	1
Davis, NB	1
Wu, SC	1
Kahn, J	1
Alou, L	1
Giménez, MJ	1
Sevillano, D	1
Aguilar, L	1
Cafini, F	1
Echeverría, O	1
Pérez-Trallero, E	1
Prieto, J	1
Sollet, JP	1
Cantón, R	1
Graninger, W	1
Concia, E	1
Marchetti, F	1
Lynch, JP	1
Karwat, KJ	1
Grabczak, M	1
Chazan, R	1
Tribble, DR	1
Sanders, JW	1
Pang, LW	1
Mason, C	1
Pitarangsi, C	1
Baqar, S	1
Armstrong, A	1
Hshieh, P	1
Fox, A	1
Maley, EA	1
Lebron, C	1
Faix, DJ	1
Lawler, JV	1
Nayak, G	1
Lewis, M	1
Bodhidatta, L	1
Scott, DA	1
DuPont, HL	1
Lee, SY	1
Fan, HW	1
Sutherland, C	1
DeRyke, AC	1
Nicolau, DP	2
Shin, JH	1
Jung, HJ	1
Kim, HR	1
Jeong, J	1
Jeong, SH	1
Kim, S	1
Lee, EY	1
Lee, JN	1
Chang, CL	1
Bradley, JS	1
Arguedas, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia[NCT01168713]	Phase 2	132 participants (Actual)	Interventional	2010-08-31	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00079885]	Phase 3	430 participants (Actual)	Interventional	2003-11-30	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00081575]	Phase 3	434 participants (Actual)	Interventional	2004-01-31	Completed
Multicenter, Double-Blind Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days vs. Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults[NCT00236821]	Phase 3	530 participants (Actual)	Interventional	2001-03-31	Completed
Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial[NCT04089787]	Phase 4	564 participants (Anticipated)	Interventional	2019-09-18	Recruiting
Statins for the Early Treatment of Sepsis[NCT00528580]	Phase 2	68 participants (Actual)	Interventional	2008-02-29	Terminated (stopped due to Inadequate recruitment)
Suitability of Antibiotic Treatment for Community-acquired Pneumonia[NCT01661920]		602 participants (Actual)	Interventional	2012-01-31	Completed
STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290]	Phase 3	588 participants (Actual)	Interventional	2016-03-31	Completed
A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting[NCT00034736]	Phase 3	691 participants (Actual)	Interventional	2002-08-31	Completed
A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Tr[NCT00431678]	Phase 3	738 participants (Actual)	Interventional	2004-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Normalization of vital signs for each subject enrolled. This is expressed as a mean time to normalization for each +/- standard error. (NCT00528580)
Timeframe: 24 hours

Failure or Recurrence (FoR)

Intervention	days (Mean)
Treatment Group	3
Control Group	3

probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)

Failure or Recurrence (FoR)

Intervention	Participants (Count of Participants)
Regimen A (Long Regimen)	0
Regimen B (Control Regimen)	17
Regimen C (Oral Regimen)	4
Regimen D (6-month Regimen)	0

The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only

Favourable Outcome After Long-term Follow-up (132 Weeks)

Intervention	Participants (Count of Participants)
Regimen B (Control Regimen)	14
Regimen D (6-month Regimen)	2

The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks

Proportion of Patients With Acquired Drug Resistance

Intervention	Participants (Count of Participants)
Regimen A (Long Regimen)	17
Regimen B (Control Regimen)	126
Regimen C (Oral Regimen)	152
Regimen D (6-month Regimen)	115

The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks

STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)

Intervention	Participants (Count of Participants)
Regimen A (Long Regimen)	0
Regimen B (Control Regimen)	5
Regimen C (Oral Regimen)	5
Regimen D (6-month Regimen)	3

The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks

Article	Year
An update on Legionella. Current opinion in infectious diseases, 2010, Volume: 23, Issue:2 Topics: Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Community-Acquired Infections; Cross Infec	2010
[Therapeutic experience with levofloxacin in pneumonia and COPD]. Le infezioni in medicina, 2009, Volume: 17 Suppl 5 Topics: Algorithms; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Cross In	2009
Levofloxacin in the treatment of community-acquired pneumonia. Expert review of anti-infective therapy, 2010, Volume: 8, Issue:5 Topics: Aged; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Humans; Levofl	2010
Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert review of anti-infective therapy, 2010, Volume: 8, Issue:11 Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired	2010
Levofloxacin for the treatment of respiratory tract infections. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:8 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cross Infection; Humans; Levofloxacin; Ofloxac	2012
[Levofloxacine for the treatment of pneumococcal pneumonia: results of a meta-analysis]. Revue de pneumologie clinique, 2003, Volume: 59, Issue:6 Topics: Acute Disease; Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Humans;	2003
A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia. Clinical cornerstone, 2003, Volume: Suppl 3 Topics: Community-Acquired Infections; Fluoroquinolones; Humans; Ofloxacin; Pneumonia, Pneumococcal; Safety;	2003
Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs). Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 2 Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infecti	2004
New insights in the treatment by levofloxacin. Chemotherapy, 2004, Volume: 50 Suppl 1 Topics: Anti-Infective Agents; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Resista	2004
Value of short-course antimicrobial therapy in community-acquired pneumonia. International journal of antimicrobial agents, 2005, Volume: 26 Suppl 3 Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials, Phase III as Topic; Community-	2005
Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2006, Volume: 12 Suppl 3 Topics: Adult; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistan	2006
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Current medical research and opinion, 2006, Volume: 22, Issue:5 Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Re	2006
Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. International journal of antimicrobial agents, 2006, Volume: 28 Suppl 2 Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Community-Acquired Infections; Fluoroquinolones; Humans;	2006
Levofloxacin for the treatment of community-acquired pneumonia. Expert review of anti-infective therapy, 2006, Volume: 4, Issue:5 Topics: Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Pneumonia	2006
Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs, 2008, Volume: 68, Issue:4 Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Community-Acquired Infections; Drug Resistance	2008
New generations of quinolones: with particular attention to levofloxacin. Connecticut medicine, 1997, Volume: 61, Issue:5 Topics: Anti-Infective Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxa	1997
[Clinical experience of levofloxacin in community acquired pneumonia]. Enfermedades infecciosas y microbiologia clinica, 1999, Volume: 17 Suppl 1 Topics: Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Levofloxac	1999
[Levofloxacin for prevalent infections in primary care medicine]. Enfermedades infecciosas y microbiologia clinica, 1999, Volume: 17 Suppl 1 Topics: Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Humans; Levofloxacin; Of	1999
The use of levofloxacin in the treatment of respiratory tract infection. Journal of chemotherapy (Florence, Italy), 2000, Volume: 12 Suppl 4 Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infec	2000
What have we learned from pharmacokinetic and pharmacodynamic theories? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Mar-15, Volume: 32 Suppl 1 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Resistanc	2001
Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimens. Chemotherapy, 2001, Volume: 47 Suppl 4 Topics: Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Female; Humans; Ma	2001
Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity). Chemotherapy, 2001, Volume: 47 Suppl 4 Topics: Age Factors; Aged; Anti-Infective Agents; Community-Acquired Infections; Comorbidity; Drug Resistanc	2001
[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2001, Volume: 46, Issue:7 Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infec	2001

Article	Year
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Double-Blind Method; Fema	2013
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagnostic microbiology and infectious disease, 2008, Volume: 61, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I	2008
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagnostic microbiology and infectious disease, 2008, Volume: 61, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I	2008
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagnostic microbiology and infectious disease, 2008, Volume: 61, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I	2008
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagnostic microbiology and infectious disease, 2008, Volume: 61, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I	2008
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagnostic microbiology and infectious disease, 2009, Volume: 63, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Haem	2009
Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. Journal of chemotherapy (Florence, Italy), 2008, Volume: 20 Suppl 1 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination	2008
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC pulmonary medicine, 2009, Sep-09, Volume: 9 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Diarrhea; Dose-Respon	2009
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2009, Volume: 15, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; China; Co	2009
Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:2 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Doxycycline;	2010
High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study. Clinical drug investigation, 2012, Sep-01, Volume: 32, Issue:9 Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Hum	2012
Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin. BMC infectious diseases, 2012, Jul-19, Volume: 12 Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blin	2012
A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clinical therapeutics, 2002, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug Thera	2002
[Community-acquired pneumonia: usefulness of clinical presentation in the selection of antibiotic treatment]. Medicina clinica, 2002, Nov-16, Volume: 119, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithro	2002
[Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization]. Anales de medicina interna (Madrid, Spain : 1984), 2002, Volume: 19, Issue:12 Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Clavulanic Acid; Commun	2002
Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy. The Journal of antimicrobial chemotherapy, 2003, Volume: 51, Issue:3 Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Clostridioides difficile; Commun	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le	2003
Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2004, Volume: 23, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Dose-Response R	2004
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Current medical research and opinion, 2004, Volume: 20, Issue:4 Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Inf	2004
Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia. Chemotherapy, 2004, Volume: 50 Suppl 1 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Azi	2004
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Current medical research and opinion, 2004, Volume: 20, Issue:9 Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Drug Administrati	2004
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. The European respiratory journal, 2004, Volume: 24, Issue:4 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis	2004
Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treatments in respiratory medicine, 2004, Volume: 3, Issue:5 Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Azithromycin; Canada; Ceftriaxone; Community-Acqu	2004
Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. International journal of antimicrobial agents, 2005, Volume: 25, Issue:1 Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Cohort Studies; Community-Acquired Infecti	2005
Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Aged; Anti-Bacterial Agents; Capillary Permeability; Community-Acquired Infections; Creatinine; Crit	2005
Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Annals of internal medicine, 2005, Feb-01, Volume: 142, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Commun	2005
Levofloxacin in the treatment of pneumonia in intensive care unit patients. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:6 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Critical Illness; Cross Infection	2004
Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest, 2005, Volume: 128, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Cefotaxime; Chi-Square Distribution; Community-Acquired Infectio	2005
Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:10 Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Chemistry, Pharmaceutical; Community-Acquired Infe	2005
A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Clinical therapeutics, 2005, Volume: 27, Issue:8 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method;	2005
A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial. Chest, 2005, Volume: 128, Issue:5 Topics: Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Costs and Cos	2005
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest, 2005, Volume: 128, Issue:5 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Comorb	2005
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jan-01, Volume: 42, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double	2006
Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respiratory medicine, 2006, Volume: 100, Issue:12 Topics: Aged; Anti-Bacterial Agents; Bacteremia; Community-Acquired Infections; Drug Administration Schedule	2006
Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2006, Volume: 78, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Community-Acquired Infections; Drug Administr	2006
Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Feb-01, Volume: 44, Issue:3 Topics: Adult; Anti-Bacterial Agents; Azithromycin; Campylobacter Infections; Campylobacter jejuni; Communit	2007
Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. The Pediatric infectious disease journal, 2007, Volume: 26, Issue:10 Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ceftriaxone; Child	2007
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. Current medical research and opinion, 2008, Volume: 24, Issue:5 Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Cost of Illness; Co	2008
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, May-15, Volume: 46, Issue:10 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Community-Acqu	2008
Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1994, Volume: 13, Issue:8 Topics: Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Clavulanic Acids; Community	1994
Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. The Journal of antimicrobial chemotherapy, 1996, Volume: 37 Suppl A Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Community-Acquire	1996
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:9 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone	1997
Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:9 Topics: Acute Disease; Adolescent; Adult; Anti-Infective Agents; Community-Acquired Infections; Female; Fluo	1998
A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scandinavian journal of infectious diseases, 1998, Volume: 30, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Comm	1998
[Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]. Presse medicale (Paris, France : 1983), 1999, Nov-20, Volume: 28, Issue:36 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Clavulanic Acid; Community	1999
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA, 2000, Feb-09, Volume: 283, Issue:6 Topics: Aged; Anti-Infective Agents; Canada; Community-Acquired Infections; Critical Pathways; Female; Hospi	2000
Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clinical therapeutics, 2000, Volume: 22, Issue:2 Topics: Aged; Anti-Infective Agents; Canada; Cluster Analysis; Community-Acquired Infections; Critical Pathw	2000
Predictors of symptom resolution in patients with community-acquired pneumonia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 31, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gastro	2000
[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]. Medicina clinica, 2000, Nov-04, Volume: 115, Issue:15 Topics: Administration, Oral; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Varian	2000
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clinical therapeutics, 2001, Volume: 23, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microb	2001
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. Pharmacotherapy, 2001, Volume: 21, Issue:7 Pt 2 Topics: Administration, Oral; Adult; Anti-Infective Agents; Canada; Community-Acquired Infections; Critical	2001
A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clinical therapeutics, 2002, Volume: 24, Issue:5 Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Delayed-Action Pr	2002

Article	Year
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6 Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug R	2007
Efflux pump activity, biofilm formation and antibiotic resistance profile of Klebsiella spp. isolated from clinical samples at Lagos University Teaching Hospital. BMC research notes, 2020, May-26, Volume: 13, Issue:1 Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Biofilms; Cefuroxime; Cells, Cultured; Community-Acq	2020
Risk factors for quinolone-resistance in women presenting with Escherichia coli acute pyelonephritis. Medecine et maladies infectieuses, 2014, Volume: 44, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Catchment Area, Health; Cohort St	2014
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study. The European respiratory journal, 2015, Volume: 46, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections;	2015
Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Hospital practice (1995), 2017, Volume: 45, Issue:1 Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired I	2017
[Necrotizing folliculitis in Behçet's disease]. La Revue de medecine interne, 2009, Volume: 30, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Bacterial Toxins; Behcet	2009
Pathotype and susceptibility profile of a community-acquired methicillin-resistant Staphylococcus aureus strain responsible for a case of severe pneumonia. Diagnostic microbiology and infectious disease, 2009, Volume: 63, Issue:1 Topics: Adult; Bacterial Proteins; Bacterial Toxins; Community-Acquired Infections; DNA Primers; Exotoxins;	2009
Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Current medical research and opinion, 2009, Volume: 25, Issue:4 Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug T	2009
Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia. BMC infectious diseases, 2009, Mar-25, Volume: 9 Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Blood	2009
Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response. Research in microbiology, 2009, Volume: 160, Issue:3 Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Ciprofloxacin; Comm	2009
Hypoglycemia associated with the use of levofloxacin. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Jun-01, Volume: 66, Issue:11 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Diabetes Mellitus, Type 2; Drug Interactions;	2009
Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance. Postgraduate medicine, 2002, Volume: 112, Issue:3 Suppl Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Doxycycline; Drug R	2002
Acinetobacter lwoffii: bacteremia associated with acute gastroenteritis. Travel medicine and infectious disease, 2009, Volume: 7, Issue:5 Topics: Acinetobacter; Acinetobacter Infections; Acute Disease; Anti-Bacterial Agents; Bacteremia; Community	2009
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2010, Volume: 16, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Anti-Bacterial Agents; Base Seq	2010
[Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?]. Medicina clinica, 2010, Oct-16, Volume: 135, Issue:12 Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infectio	2010
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. Current medical research and opinion, 2010, Volume: 26, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Ambulatory Care; Anti-Infective Agents; Aza	2010
[Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia]. Medecine et maladies infectieuses, 2010, Volume: 40, Issue:6 Topics: Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Cohort Studies; Co	2010
Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2010, Volume: 14, Issue:4 Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Chi-Square Distribution; Clarithromycin;	2010
Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions. Yonsei medical journal, 2010, Volume: 51, Issue:3 Topics: Achilles Tendon; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Disease Susceptibility	2010
[Experience accumulated in hospital setting with levofloxacin, in monotherapy and in association therapy]. Le infezioni in medicina, 2009, Volume: 17 Suppl 5 Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Community-Acquired Infect	2009
Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis. Advances in therapy, 2010, Volume: 27, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Community-Acquired Infections	2010
[Levofloxacin in children]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2010, Volume: 17 Suppl 4 Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Child; Community-Acquired Infections; Humans; Le	2010
Community-acquired methicillin-resistant Staphylococcus aureus meningitis complicated by cerebral infarction. Role of antibiotic combination of linezolid plus levofloxacin. Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:18 Topics: Acetamides; Adult; Anti-Bacterial Agents; Cerebral Infarction; Community-Acquired Infections; Drug T	2010
Brain abscesses during Proteus vulgaris bacteremia. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2011, Volume: 32, Issue:4 Topics: Anti-Bacterial Agents; Antiphospholipid Syndrome; Bacteremia; Brain; Brain Abscess; Ceftriaxone; Com	2011
Case of Legionella pneumonia complicated with pulmonary thromboembolism. Acta microbiologica et immunologica Hungarica, 2010, Volume: 57, Issue:4 Topics: Anti-Bacterial Agents; Anticoagulants; Community-Acquired Infections; Heparin; Humans; Legionnaires'	2010
First case of Legionella pneumophila native valve endocarditis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2011, Volume: 15, Issue:8 Topics: Adult; Aortic Valve; Community-Acquired Infections; Endocarditis, Bacterial; Female; Humans; Immunos	2011
[Levofloxacin. expediency of high-dose regimens in therapy of lower respiratory tract infections]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2011, Volume: 56, Issue:3-4 Topics: Community-Acquired Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin;	2011
Rapidly fatal community-acquired pneumonia due to Klebsiella pneumoniae complicated with acute myocarditis and accelerated idioventricular rhythm. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2012, Volume: 45, Issue:4 Topics: Accelerated Idioventricular Rhythm; Acidosis, Lactic; Acute Disease; Community-Acquired Infections;	2012
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. International journal of antimicrobial agents, 2012, Volume: 39, Issue:4 Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Evaluation, Preclinical; D	2012
Community acquired Pseudomonas pneumonia in an immune competent host. BMJ case reports, 2012, May-26, Volume: 2012 Topics: Adult; Anti-Bacterial Agents; Biopsy; Community-Acquired Infections; Diagnosis, Differential; Humans	2012
[Differences between species involved and fluoroquinolone resistance patterns of strains isolated from bacteriuria according to nosocomial, health-related or community-acquired onset]. Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:12 Pt 1 Topics: Anti-Bacterial Agents; Bacteriuria; Community-Acquired Infections; Cross Infection; Drug Resistance,	2012
Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort. Infection, 2013, Volume: 41, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Femal	2013
[Update on the role of levofloxacin in the management of acute community-acquired pneumonia]. Presse medicale (Paris, France : 1983), 2002, Jun-15, Volume: 31, Issue:21 Pt 2 Topics: Acute Disease; Anti-Infective Agents; Bacteremia; Community-Acquired Infections; Humans; Levofloxaci	2002
[Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year]. The Japanese journal of antibiotics, 2001, Volume: 54 Suppl B Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceph	2001
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Archives of internal medicine, 2003, Apr-14, Volume: 163, Issue:7 Topics: Adolescent; Adult; Aged; Alberta; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Azit	2003
The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. Wiener medizinische Wochenschrift (1946), 2003, Volume: 153, Issue:7-8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Child; Child, Preschool; Chlamydo	2003
A 65-year-old woman with acute cough illness and an important engagement. JAMA, 2003, May-28, Volume: 289, Issue:20 Topics: Acute Disease; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antitussive Agents; Antiviral Age	2003
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Aug-01, Volume: 37, Issue:3 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Imm	2003
High level of resistance to levofloxacin of Streptococcus pneumoniae following fluoroquinolone therapy. Infection, 2003, Volume: 31, Issue:5 Topics: Aged; Cefotaxime; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Resistance,	2003
Levofloxacin treatment failure in Haemophilus influenzae pneumonia. Emerging infectious diseases, 2003, Volume: 9, Issue:11 Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; DNA Gyrase; Electrophoresis, Gel, Pulsed	2003
[Observational study investigating the use of levofloxacin in ICU patients]. Enfermedades infecciosas y microbiologia clinica, 2004, Volume: 22, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Arrhythmias, Cardiac; B	2004
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, May-15, Volume: 38 Suppl 4 Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Comb	2004
[Resistance surveillance of common community respiratory pathogens isolated in China, 2002 - 2003]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2004, Volume: 27, Issue:3 Topics: Anti-Bacterial Agents; Cefprozil; Cephalosporins; Child, Preschool; China; Community-Acquired Infect	2004
Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest, 2004, Volume: 125, Issue:6 Topics: Clinical Trials as Topic; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Admi	2004
Lupus pneumonitis or severe acute respiratory syndrome? Lupus, 2004, Volume: 13, Issue:7 Topics: Adult; Antiviral Agents; China; Community-Acquired Infections; Diagnosis, Differential; Female; Huma	2004
Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). International journal of antimicrobial agents, 2004, Volume: 24, Issue:5 Topics: Adolescent; Adult; Aged; Area Under Curve; Community-Acquired Infections; Drug Administration Routes	2004
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. Journal of clinical microbiology, 2004, Volume: 42, Issue:11 Topics: Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; Drug Resistance, Bacterial	2004
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagnostic microbiology and infectious disease, 2005, Volume: 51, Issue:1 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Levofloxac	2005
Summaries for patients. Can patients with pneumonia take their antibiotics at home? Annals of internal medicine, 2005, Feb-01, Volume: 142, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Commun	2005
Decisions about treating community-acquired pneumonia. Annals of internal medicine, 2005, Feb-01, Volume: 142, Issue:3 Topics: Ambulatory Care; Anti-Bacterial Agents; Community-Acquired Infections; Hospitalization; Humans; Oflo	2005
[Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. Pathologie-biologie, 2005, Volume: 53, Issue:2 Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Community-Acquired Infections; Escherichia col	2005
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care. Current medical research and opinion, 2005, Volume: 21, Issue:2 Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infection	2005
[Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema]. Enfermedades infecciosas y microbiologia clinica, 2005, Volume: 23, Issue:5 Topics: Aged; Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinol	2005
An analysis of a community-acquired pathogen in a Kentucky community: methicillin-resistant Staphylococcus aureus. The Journal of the Kentucky Medical Association, 2005, Volume: 103, Issue:5 Topics: Adult; Anti-Bacterial Agents; Cefazolin; Clindamycin; Community-Acquired Infections; Erythromycin; F	2005
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagnostic microbiology and infectious disease, 2005, Volume: 52, Issue:2 Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; DNA, Bacterial; Drug Resistance,	2005
Monotherapy in severe community-acquired pneumonia: is it worthy? Chest, 2005, Volume: 128, Issue:1 Topics: Anti-Bacterial Agents; Cefotaxime; Community-Acquired Infections; Drug Therapy, Combination; Humans;	2005
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. International journal of antimicrobial agents, 2005, Volume: 26, Issue:2 Topics: Adult; Aged; Community-Acquired Infections; Drug Administration Schedule; Epidemiologic Methods; Flu	2005
[Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2005, Volume: 50, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Bacterial Infections; Ce	2005
What's in a day? Chest, 2005, Volume: 128, Issue:5 Topics: Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Humans; Length of Stay; Ofloxaci	2005
Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC infectious diseases, 2005, Nov-24, Volume: 5 Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; DNA Topoisomerases,	2005
[Assessment of the management of community-acquired pneumonia in adults outpatients]. Revista medica de Chile, 2005, Volume: 133, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Amoxicillin; Anti-Bacterial Agents; Chi	2005
Detection of methicillin-resistant Staphylococcus aureus strains resistant to multiple antibiotics and carrying the Panton-Valentine leukocidin genes in an Algiers hospital. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:3 Topics: Algeria; Alleles; Anti-Bacterial Agents; Bacterial Toxins; Community-Acquired Infections; Drug Resis	2006
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:2 Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Community-Acquired Infections; Drug Resistance,	2006
Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. International journal of antimicrobial agents, 2006, Volume: 28 Suppl 2 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Respiratory T	2006
[Efficacy and safety of levofloxacin treatment of community--acquired pneumonia in hospitalized patients]. Pneumonologia i alergologia polska, 2006, Volume: 74, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Hospitalizati	2006
Azithromycin for the self-treatment of traveler's diarrhea. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Feb-01, Volume: 44, Issue:3 Topics: Anti-Bacterial Agents; Azithromycin; Campylobacter Infections; Campylobacter jejuni; Community-Acqui	2007
Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus. Drugs in R&D, 2007, Volume: 8, Issue:2 Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Culture Media; Epithelium; Fluo	2007
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Er	2007
Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case. The American journal of the medical sciences, 2008, Volume: 335, Issue:2 Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin;	2008
Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clinical therapeutics, 2008, Volume: 30, Issue:2 Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Ana	2008
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Current medical research and opinion, 2008, Volume: 24, Issue:3 Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Co	2008
[Mixte community-acquired Legionella pneumophila and Staphylococcus aureus pneumonia]. Presse medicale (Paris, France : 1983), 1993, Sep-18, Volume: 22, Issue:27 Topics: Adult; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Legionnaires' Disea	1993
Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections. BMJ (Clinical research ed.), 1994, Jan-15, Volume: 308, Issue:6922 Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Community-Acquired Infections; Female; Humans; Mal	1994
Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. The Journal of antimicrobial chemotherapy, 1996, Volume: 38 Suppl A Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Ciprofloxacin; Community-Acquired Infections; Drug Re	1996
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:5 Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Met	1998
Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. The Journal of antimicrobial chemotherapy, 1999, Volume: 43 Suppl C Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bronchitis; Chronic Disease; Commun	1999
From the Food and Drug Administration. JAMA, 2000, Apr-05, Volume: 283, Issue:13 Topics: Anti-HIV Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Interactions; Enzyme Inh	2000
Community-acquired pneumonia: reality revisited. The American journal of medicine, 2000, Apr-01, Volume: 108, Issue:5 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Doxycycline; Gram-Negat	2000
52-year-old man with shortness of breath. Mayo Clinic proceedings, 2000, Volume: 75, Issue:4 Topics: Anti-Infective Agents; Community-Acquired Infections; Diagnosis, Differential; Dyspnea; Humans; Male	2000
Oral levofloxacin in the treatment of community-acquired pneumonia. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2000, Volume: 4, Issue:2 Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Hum	2000
Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:5 Topics: Anti-Infective Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Infections	2000
Demographic characteristics of patients with community-acquired bacteriuria and susceptibility of urinary pathogens to antimicrobials in northern Israel. The Israel Medical Association journal : IMAJ, 2000, Volume: 2, Issue:6 Topics: Adolescent; Adult; Aged; Amoxicillin; Bacteriuria; Cephalexin; Child; Child, Preschool; Community-Ac	2000
[A new antibiotic: levofloxacine]. Presse medicale (Paris, France : 1983), 2000, Jun-17, Volume: 29, Issue:21 Topics: Anti-Infective Agents; Bronchitis; Community-Acquired Infections; Humans; Ofloxacin; Pneumonia; Sinu	2000
Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan. The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Cefdinir; Cephalosporins; Community-Acquired Infections; Drug Re	2000
The emergence of resistance to levofloxacin before clinical use in a university hospital in Singapore. The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:5 Topics: Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Levofloxac	2000
Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Nov-15, Volume: 57 Suppl 3 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infect	2000
Approaches to drug therapy, formulary, and pathway management in a large community hospital. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Nov-15, Volume: 57 Suppl 3 Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Community-Acquired Inf	2000
Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia. Infection control and hospital epidemiology, 2000, Volume: 21, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxon	2000
[Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)]. Revue medicale de Liege, 2000, Volume: 55, Issue:11 Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Bronchit	2000
Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation. The Medical journal of Malaysia, 2000, Volume: 55, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Community-A	2000
Aspiration pneumonia. The New England journal of medicine, 2001, Jun-14, Volume: 344, Issue:24 Topics: Anti-Infective Agents; Bacteria, Anaerobic; Community-Acquired Infections; Cross Infection; Humans;	2001
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience. Pharmacotherapy, 2001, Volume: 21, Issue:7 Pt 2 Topics: Administration, Oral; Aged; Anti-Infective Agents; APACHE; Ciprofloxacin; Community-Acquired Infecti	2001
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. International journal of antimicrobial agents, 2001, Volume: 18, Issue:4 Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoro	2001
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. The American journal of medicine, 2001, Dec-17, Volume: 111 Suppl 9A Topics: Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Community-Acquired Infections; Fluoroqui	2001
Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia. Chinese medical journal, 2001, Volume: 114, Issue:2 Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Bronchoalveolar Lavage Fluid; Community-Acquired Infec	2001
Levofloxacin-induced toxic epidermal necrolysis in an elderly patient. Pharmacotherapy, 2002, Volume: 22, Issue:6 Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Fluid Therapy; Humans; Levofloxa	2002

ofloxacin and Community Acquired Infection

Research Excerpts

Research

Studies (168)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Time to Clinical Stability

Failure or Recurrence (FoR)

Failure or Recurrence (FoR)

Favourable Outcome After Long-term Follow-up (132 Weeks)

Proportion of Patients With Acquired Drug Resistance

STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)

Reviews

Trials

Other Studies